Best Case
15%Real-time review becomes a broadly used FDA operating model for many interventional trials.
Forecast dossier
FDA is likely to normalize real-time clinical trial data review for selected sponsors
FDA's April 28 real-time clinical trials announcement, paired with a live pilot involving sponsor and technology partners, suggests a durable shift toward continuous or near-continuous data sharing during trials. The most likely near-term effect is not universal adoption, but a new regulatory lane for early-phase studies that can support faster safety monitoring and earlier go or no-go decisions. ( )
Verdict: Likely to become a real regulatory option, but only for a subset of trials at first.
Date
Apr 28, 2026
Reliability
79
Harm potential
Medium
Scenario odds
Baseline
50%FDA adopts real-time review selectively for pilots and high-priority sponsors.
Adverse Case
25%Data quality, privacy, or workload issues keep the program narrow and slow.
Wildcard
10%The pilot quickly expands into a cross-agency data platform with sponsors, EHR vendors, and sites.
Timeline projections
1-Year
Pilot phase
Developments: A limited set of trials test continuous data transfer and FDA review workflows.
Risks: Technical integration and governance problems.
Outlook: The concept becomes operational for a narrow group of sponsors.
2-Year
Early standard-setting
Developments: FDA likely issues practical expectations for formats, endpoints, and review timing.
Risks: Inconsistent sponsor implementation.
Outlook: The agency begins defining what counts as acceptable real-time evidence.
3-Year
Selective scale-up
Developments: More early-phase oncology and specialty programs may adopt the model.
Risks: If results are mixed, adoption stalls.
Outlook: The workflow becomes a recognized option rather than an experiment.
5-Year
New trial infrastructure norm
Developments: Sponsors increasingly build studies around continuous data capture and analysis.
Risks: Cost and interoperability barriers could limit spread.
Outlook: A durable redesign of some clinical development pipelines.
10-Year
Continuous regulatory oversight
Developments: FDA review may rely much more on live data streams for selected product classes.
Risks: Privacy and cybersecurity challenges.
Outlook: The agency could move from periodic to more continuous oversight in specific settings.
20-Year
Integrated evidence ecosystem
Developments: Clinical research, EHRs, and regulatory review may be tightly linked for many trials.
Risks: Governance failures or public trust issues.
Outlook: A major structural shift in drug development infrastructure.
50-Year
Historical inflection point
Developments: Real-time trial review could be remembered as one of the core changes that compressed development timelines.
Risks: Future systems may replace it.
Outlook: Potentially foundational if the model scales successfully.
Planning prompts to verify
- Monitor the Federal Register notice and RFI responses.
- Track which sponsors and therapeutic areas join the pilot.
- Watch whether FDA issues guidance on acceptable real-time data standards.